Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PG

Both items are early-phase, investigator-sponsored trials with Incyte Corporation as collaborator rather than lead sponsor.

• Ohio State University Comprehensive Cancer Center registered a Phase IIa trial (NCT07780838) testing first-line cyclical gemcitabine, cisplatin, and durvalumab alternating with pemigatinib for advanced biliary tract cancers with FGFR2 alterations¹. The study is recruiting, with an estimated enrollment of 29 participants¹, and its primary objective is to evaluate the efficacy of cyclical therapy alternating with chemoimmunotherapy and pemigatinib in patients with advanced cholangiocarcinoma and FGFR2 fusions and rearrangements, or other gain-of function alterations involved in FGFR¹.
• Oregon Health and Science University registered a Phase 2 pilot study (NCT07783412), acronym TRIUMPH, evaluating topical ruxolitinib (OPZELURA) as a treatment for adults with Pyoderma Gangrenosum (PG), a chronic inflammatory skin condition that causes painful ulcers². The trial is not yet recruiting and plans to enroll approximately 12 participants who will apply ruxolitinib cream twice daily for 24 weeks while continuing standard wound care², with the primary endpoint being the proportion of participants achieving complete re-epithelialization of the target ulcer at Week 24². Incyte funds the study, which is sponsored by OHSU.